Apex Biotechnology Profit Margin

The latest profit margin for 1733.TW is 10.21% as of June 2026. That compares with 7.98% in the prior-year period — up 27.9% year over year. That is above the Healthcare sector average of 9.48%. Investors often review this figure alongside Apex Biotechnology's historical trend and sector peers before judging valuation or financial health.

Over the past year, 1733.TW's profit margin moved from 7.98% to 10.21% — a 27.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Apex Biotechnology's valuation or profitability profile.

Against Healthcare companies, 1733.TW currently prints 10.21% for profit margin, while the sector average sits near 9.48%. That is roughly 7.7% above the sector mean. Large gaps often invite a closer look at Apex Biotechnology's growth, margins, and balance sheet.

Profit Margin shows how effectively Apex Biotechnology converts resources into returns. At 10.21%, 1733.TW may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 7.98% in the prior-year period — up 27.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting 1733.TW's profit margin (10.21%), review year-over-year change from 7.98%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.